Sanofi Chief Executive Officer Olivier Brandicourt has announced a number of changes to the company's Executive Committee, supporting Sanofi's recently announced 2020 Strategic Roadmap.

As of June 1, 2016, the company's Executive Committee, chaired by Olivier Brandicourt, will be comprised of the following members:
Olivier Charmeil, Executive Vice President and General Manager, General Medicines and Emerging Markets
Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular
Carsten Hellmann, Executive Vice President and General Manager of Merial (until Dec. 31, 2016–see below)
Karen Linehan, Executive Vice President, Legal Affairs and General Counsel
David Loew, Executive Vice President and General Manager of Sanofi Pasteur
Philippe Luscan, Executive Vice President, Global Industrial Affairs
Muzammil Mansuri, PhD, Executive Vice President, Strategy & Business Development
David Meeker, MD, Executive Vice President and General Manager of Sanofi Genzyme
Ameet Nathwani, MD, Executive Vice President, Medical Affairs
Roberto Pucci, Executive Vice President, Human Resources
Elias Zerhouni, MD, President, Global Research & Development.

The company has also announced that Pascale Witz, Executive Vice President, Diabetes & Cardiovascular, will leave the company on June 1. Pascale joined Sanofi in July 2013.

Carsten Hellmann, Executive Vice President, Merial, has accepted a position as President and CEO of ALK but will stay with Sanofi until the end of the year to support the strategic business swap project with Boehringer Ingelheim.

In addition, Sanofi plans to name at a later date an Executive Vice President, Consumer Healthcare (CHC) who will be a member of the Executive Committee. This person will lead a newly created CHC global business unit, which will be formed following the anticipated completion of the business swap announced in December 2015 that consists of Sanofi's animal health business Merial and Boehringer Ingelheim's CHC business.

Finally, Suresh Kumar, Executive Vice President, External Affairs, has decided to return to the United States for personal reasons. Given the challenging US operating environment and impending change in government leadership, Suresh has agreed to continue to represent Sanofi's interest in the US until the year-end. Olivier Brandicourt will serve as acting head of External Affairs until a replacement is found to succeed Suresh.

Source: Sanofi